CRDF
CRDF
NASDAQ · Biotechnology

Cardiff Oncology Inc

$1.67
-0.06 (-3.47%)
As of May 16, 9:40 PM ET ·
Financial Highlights (FY 2026)
Revenue
612.1K
Net Income
-47,180,893
Gross Margin
100.0%
Profit Margin
-7,732.0%
Rev Growth
+15.0%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 612.1K 532.3K 16.05M 19.98M
Gross Profit 612.1K 532.3K 9.01M 11.22M
Operating Income -50,538,008 -39,554,924 -2,950,777 -3,087,601
Net Income -47,180,893 -36,927,388 -3,462,613 -3,502,482
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Rev Growth +15.0% +15.0% +0.8% +4.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.47M 47.77M
Total Equity 57.67M 59.42M
D/E Ratio 0.67 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -50,000,743 -41,308,553 -3,307,317 -3,822,507
Free Cash Flow -2,137,974 -3,204,130